Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 10/20 | 0.49 |
| ▸ | REN | P00797 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PEPD | P12955 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
| ▸ | THPO | P40225 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL109013 | 1.00 | ACE (0.49) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL3931067 | 1.00 | ACE (0.49) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL2177826 | 0.85 | ACE (0.51) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL2177815 | 0.85 | ACE (0.51) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL9166405 | 0.81 | ACE (0.49) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL14215476 | 0.81 | ACE (0.40) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL21081655 | 0.81 | FKBP1A (0.54) | LMNAPEPDRAB9A | |
| N-Acetylproline SCHEMBL428477 | 0.80 | ACE (0.54) | ACERENLMNAHSD17B10CYP2C19 | |
| N-Acetylproline SCHEMBL428476 | 0.80 | ACE (0.54) | ACERENLMNAHSD17B10CYP2C19 | |
| N-Acetylproline SCHEMBL358379 | 0.80 | ACE (0.54) | ACERENLMNAHSD17B10CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3355706-B1 | GUM BASES AND CHEWING GUMS USING THERMOSENSITIVE POLYMERS | WRIGLEY W M JUN CO (US) | 2020-11-04 | — | — | EP | claimed |
| US-20190110497-A1 | GUM BASES AND CHEWING GUMS USING THERMOSENSITIVE POLYMERS | WM. WRIGLEY JR. COMPANY | 2019-04-18 | — | — | US | claimed |
| EP-3355706-A1 | GUM BASES AND CHEWING GUMS USING THERMOSENSITIVE POLYMERS | Wm. Wrigley Jr. Company (US) | 2018-08-08 | — | — | EP | claimed |
| WO-2008055482-A1 | CONTACT LENS MATERIAL | WOEHLK CONTACT-LINSEN GMBH (DE) | 2008-05-15 | — | — | WO | claimed |
| EP-0417564-B1 | UV-curable copolymers | BASF AG (DE) | 1995-06-21 | — | — | EP | claimed |
| US-11873282-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873282-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-11648234-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2023-05-16 | — | — | US | disclosed |
| US-11648234-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230041951-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | Oncternal Therapeutics, Inc. | 2023-02-09 | — | — | US | disclosed |
| US-11273147-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2022-03-15 | — | — | US | disclosed |
| US-20210253525-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2021-08-19 | — | — | US | disclosed |
| EP-0198352-A2 | Method for preparing (+)R-2-methyl-hexane-1,2-diol | MILES INC. (US) | 1986-10-22 | — | — | EP | disclosed |
| US-4604451-A | Novel functionalized resin derived from polyallylamine | NITTO BOSEKI CO., LTD. (JP) | 1986-08-05 | — | — | US | disclosed |
| EP-0154742-A2 | Novel functionalized resin derived from polyallylamine | NITTO BOSEKI CO., LTD. (JP) | 1985-09-18 | — | — | EP | disclosed |
| US-4450275-A | HYPOTENSIVE AGENTS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1984-05-22 | — | — | US | disclosed |
| EP-0038117-A1 | Methods for preparing anti-hypertensive agents | UNIVERSITY OF MIAMI (US) | 1981-10-21 | — | — | EP | disclosed |
| US-4261895-A | HYPOTENSIVE AGENTS | SANDOZ LTD. (CH) | 1981-04-14 | — | — | US | disclosed |
| US-4154840-A | Antihypertensive pipecolic acid derivatives | E. R. SQUIBB & SONS, INC. (US) | 1979-05-15 | — | — | US | disclosed |
| US-4105776-A | ANGIOTENSIN CONVERTING ENZYME INHIBITORS, HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1978-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041951-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | AR, AHR, BRDT | ACE 2199/4885REN 2209/4885LMNA 553/4885 |
| US-11648234-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use | AR, BRCA1, FSHR | ACE 1833/4885REN 2429/4885LMNA 627/4885 |
| US-11273147-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, AHR, BRDT | ACE 2199/4885REN 2209/4885LMNA 553/4885 |
| US-20210253525-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | AR, AHR, BRDT | ACE 2199/4885REN 2209/4885LMNA 553/4885 |
| US-11873282-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, AHR, BRDT | ACE 2199/4885REN 2209/4885LMNA 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.